An Autoantibody Based Protein Microarray Blood Test to Enhance the Specificity of a Negative Screening Mammogram

Background: Current screening mammography for breast cancer is associated with misdiagnosis in as many as 30% of cases. Objectives: To develop and clinically evaluate a unique autoantibody based protein microarray blood test to improve the accuracy of breast cancer screening. Materials and Methods: A microarray was constructed from commercial antigens and antigens selected from screened cDNA libraries of breast cancer tissue samples. A training set containing 439 healthy controls and 276 biopsy proven breast cancer cases was used to establish a set of separating models between the two groups. These models were used to assign a diagnosis to 285 blind samples from 120 breast cancer patients and 165 healthy controls. Results: The test identified 82 of the 120 breast cancer patients and 160 of the 165 healthy controls. These results can be translated into a sensitivity of 68.3% [CI: 59% -77%] and a specificity of 97% [CI: 93% -99%], with a PPV for this validation set of 94.3% (CI: 87.10% -98.11%), NPV of 80.81% [CI: 74.62% -86.05%] and an AUC of 89.2% [CI: 78% -87%]. Conclusions: The protein microarray can be utilized to reduce the false negative rate of routine screening mammography. Women with a negative mammography and a negative blood test can be reassured and encouraged to continue routine breast cancer screening. A positive test should alert the physician about the possible presence of a breast cancer not detected by routine screening mammography and drive to perform additional investigation, such as breast ultrasound and MRI.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  2015-01-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.4236/ABCR.2015.41003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Dense breasts: a review of reporting legislation and available supplemental screening options.

  2014cited by this paper
• An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis

  2013cited by this paper
• Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk.

  2012cited by this paper
• On the frontline of screening for breast cancer.

  2011cited by this paper
• Autoantibodies to Tailor-Made Panels of Tumor-Associated Antigens in Breast Carcinoma

  2011cited by this paper
• Histological types of breast cancer: How special are they?

  2010cited by this paper
• Autoantibodies to Tumor-Associated Antigens in Breast Carcinoma

  2010cited by this paper
• Pattern of Serum Autoantibodies Allows Accurate Distinction between a Tumor and Pathologies of the Same Organ

  2008cited by this paper
• Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer.

  2008cited by this paper
• Toward an early diagnosis of lung cancer: An autoantibody signature for squamous cell lung carcinoma

  2008cited by this paper
• Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary

  2008cited by this paper
• Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer

  2007cited by this paper
• Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study.

  2007cited by this paper
• Advances of MUC1 as a target for breast cancer immunotherapy.

  2007cited by this paper
• Biomolecular markers of breast cancer.

  2006cited by this paper
• Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.

  2006cited by this paper
• Physician predictors of mammographic accuracy.

  2005cited by this paper
• The relationship between condom use and herpes simplex virus acquisition

  2005cited by this paper
• Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.

  2005cited by this paper
• Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis

  2005cited by this paper
• Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us?

  2004cited by this paper
• Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.

  2003cited by this paper
• Evaluation of proscriptive health care policy implementation in screening mammography.

  2003cited by this paper
• LEDGF/p75: a novel nuclear autoantigen at the crossroads of cell survival and apoptosis.

  2003cited by this paper
• Using sonography to screen women with mammographically dense breasts.

  2003cited by this paper
• Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations.

  2002cited by this paper
• Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.

  2001cited by this paper
• The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells

  2001cited by this paper
• p53 Antibodies in the sera of patients with various types of cancer: a review.

  2000cited by this paper
• Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients.

  2000cited by this paper
• Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers.

  2000cited by this paper
• Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma.

  1998cited by this paper
• HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

  1997cited by this paper
• Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients.

  1997cited by this paper
• The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line.

  1996cited by this paper
• Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.

  1993cited by this paper
• SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM

  1965cited by this paper
• Radiology

  1938cited by this paper

• No citing papers are available for this paper.